It is becoming apparent that gd T cells form an important part of the adaptive immune response. However, the ligands recognized by gd T cell receptors (TCRs) and the exact biological function of the cells that express this receptor remain unclear. Numerous studies have shown that the dominant human peripheral blood subset of gd T cells, which express a V g 9V d 2 TCR, can activate in response to low molecular weight nonpeptidic molecules. Some of these components have been purified from bacteria or parasites. We examined the activation of polyclonal gd T cell lines, clones with V g 9V d 2 and V g 9V d 1 TCRs, and gd T cells directly ex vivo in response to multiple phosphate, alkylamine and aminobisphosphonate (nBP) antigens and purified protein derivative from Mycobacterium tuberculosis (PPD). V g 9V d 2 T cells were able to respond to multiple small organic molecules of highly variable structure whereas cells expressing a similar V g 9 chain paired with a V d 1 chain failed to recognize these antigens. Thus, the TCR d chain appears to make an important contribution to the recognition of these antigens. The kinetics of responses to alkylphosphate and alkylamine antigens differ from those of responses to the nBP pamidronate. These different classes of antigen are believed to have differed mechanisms of action. Such differences explain why nBPs can be pulsed onto antigen presenting cells (APCs) and still retain their ability to activate gd T cells while alkylphosphate and alkylamine antigens cannot. We also demonstrate that a substantial proportion of the cells that produce IFN g directly ex vivo in response to PPD are gd T cells and that gd T cell activation requires contact with cells of human origin.
INTRODUCTION
The key to adaptive immunity lies in the somatic gene rearrangement of antigen receptors that produces an almost infinite array of specific configurations from a finite number of genes. There are three different types of antigen receptor: the B cell receptor (antibody), the ab T cell receptor (TCR), which generally recognizes small peptide antigens in the context of self major histocompatibility complex (MHC) molecules presented on the cell surface, and the gd TCR. These three receptors distinguish the main lymphocyte lineages: B cells, ab T cells and gd T cells. The last 40 years have seen much progress in our understanding of how B cells and ab T cells contribute to immunity. Surprisingly, the ligands recognized by the gd TCR and the exact biological role of cells that express this receptor remain unclear [1, 2] .
The potential importance of gd T cells is evident from the large number of possible gd T cell receptors (TCRs) [3] . Despite a relatively restricted number of V genes compared with ab T cells, huge diversity can be generated through the D and J gene segments and it has been estimated that approximately 10 20 different gd TCRs can be created by these gene rearrangements [3] . This is substantially more than the number of possible antibodies or ab TCRs that the human body can generate although it is not clear to what extent gd T cells exploit this potential. Hints at an important role for gd T cells in immunity come from the observed large expansions of these cells that occur in response to a wide range of pathogens. In humans, bacterial infections including Mycobacterium tuberculosis [4] , Mycobacterium leprae [5] , Salmonella typi [6] , Brucella melitensis [7] , Francisella tularensis [8] , Listeria monocytogenes [9, 10] and Ehrlichia chaffeensis [11] , viral infections including HIV [12] [13] [14] , Epstein-Barr Virus [15] and cytome-galovirus [16, 17] , yeast infection with Candida albicans [18] and parasitic infections including Plasmodium falciparum [19] , Plasmodium vivax [20] and Leishmania donovani [21] can all stimulate a dramatic expansion of gd T cells in vivo . While murine studies have shown that gd T cells are redundant and nonessential for immunity to many infectious agents (reviewed in [1] ) they are indispensable and nonredundant for immunity to other pathogens. Depletion of the gd T cell subset in mice with TCR-specific antibodies can result in an increase in bacterial titres by 2-3 orders of magnitude after infection with L. monocytogenes [22, 23] . A recent study showed that while intranasal inoculation of gd -/-mice with Nocardia asteroides led to 100% fatality within two weeks there were no deaths in gd +/+ control mice [24] . Other studies in gd -/-mice reveal a role for gd T cells in protection against Mycobacterium bovis bacillus Calmette-Guerin (BCG) [25] , M. tuberculosis [26] and L. monocytogenes [27] . In addition, recent experiments in primates highlight the adaptive nature of gd T cell responses. Macaques infected with BCG showed up to 25 fold increases in circulating V g 9V d 2 T cells and exhibited larger expansions during re-infection [28] , demonstrating that gd T cells, in common with their ab TCR-expressing cousins, possess the capacity for immunological memory. The clonotypic expansions of V g 9V d 2 T cells during BCG infection and re-infection infer antigen-specificity in primary and memory gd T cell-mediated immune responses [28] . Vaccination of humans with BCG induces a marked increase in the capacity of gd T cells to expand in vitro following stimulation with live BCG or M. tuberculosis lysate [29] . These data suggest that human gd T cells can mount a memory response [29] . The immune potency of human peripheral blood gd T cells in vivo has also been demonstrated in the SCID mouse model. Inoculation of SCID mice with human PBMC rescues mice from lethal infection with E. coli [30] . Depletion of V d 2-expressing T cells from PBMC resulted in a higher bacterial load and lower survival rate [30] .
Despite the large number of organisms known to activate gd T cells, relatively few antigens have been identified. Recent advances have described low molecular weight, nonpeptidic compounds that appear to be able to activate the dominant subset of gd T cells in human peripheral blood, those with a V g 9V d 2 TCR. These compounds include alkylphosphates, alkylamines and aminobisphosphonates (nBPs) [31] [32] [33] . Recognition of all these groups of molecules appears to be subject to strict chemical constraints as minor modifications in antigen structure abolish activity [32, 34, 35] . Many of the gd T cell phosphoantigens and the antigenic alkylamines are produced by bacteria, suggesting that the recognition of such compounds might be immunologically relevant.
In this study, we examine the recognition requirements of human gd T cells in detail. We show that V g 9 T cells expressing a V d 2 chain recognize multiple small nonpeptidic ligands. In contrast, cells isolated from human peripheral blood that express a V g 9 chain paired with a V d 1 chain fail to recognize any of these ligands. A single V g 9V d 2 T cell clone activated in response to alkylphosphate, alkylamine, and nBP antigens despite the obvious differences in their chemistry. Recognition of all these compounds was dependent on cell-cell contact. nBP ligands could be pulsed onto antigen presenting cells (APCs), while alkylphosphate and alkylamine antigens needed to be continuously present in the media to activate gd T cells. Furthermore, all these molecules were only able to activate gd T cells when the presenting cell was of human origin.
MATERIALS AND METHODS
gd T cell culture gd T cells were isolated from human peripheral blood using a magnetic bead-based separation kit (TCR g / d Microbead Kit and MS columns, Miltenyi Biotech Ltd., Bisley, UK). Once isolated, cells were resuspended in T cell medium (RPMI supplemented with penicillin, streptomycin and glutamine, 10% FCS, 10% T-STIM (BD Biosciences, Cowley, UK), 200 U/ml Proleukin (Chiron)) containing 2 ¥ 10 6 g -irradiated human peripheral blood mononuclear cells (PBMC)/ml from three unrelated donors and 2 m g/ml phytohaemagglutinin (PHA). Cells were maintained with T cell medium, and restimulated with mixed irradiated PBMC and PHA every three weeks. For cloning, the same mix was used to grow cells by limiting dilution in 96-well U-bottomed plates. The IMGT system of TCR nomenclature is used throughout this work [36] . Cells that grew were confirmed to be gd T cells with V g 9 antibody. 59/60 of V g 9-expressing clones also stained with V d 2 antibody. The remaining clone expressed a V d 1 receptor. Two of the best growing V g 9V d 2 clones and the V g 9V d 1 clone were taken forward for further examination. Sequencing showed that both V g 9Vd 2 T cells expressed an identical TCR.
Sequencing gd TCRs TCR usage in gd T cell clones was characterized with a molecular analysis of gene expression. RNA was isolated from 10 6 cells in TriReagent (Sigma-Aldrich Company Ltd., Gillingham, UK). cDNA was prepared using a poly T oligonucleotide and reverse transcriptase enzyme. Polymerase chain reaction (PCR) was carried out for the gamma chain and for the delta chain using a full panel of variable region primers and a reverse primer to anneal to the constant region. The results of the PCR were consistent with the flow cytometric analysis and demonstrated both a Vg 9Vd1 and a Vg 9Vd 2 clone.
Antibodies
The following antibodies were used for flow cytometric analysis: FITC-conjugated mouse anti-human Vd 2 mAb clone B6·1 (BD Biosciences Pharmingen, Cowley, UK), FITC-conjugated mouse anti-human Vg 9 mAb clone 7A5 (Endogen), FITC-conjugated mouse anti-human Vd 1 mAb clone TS8·2 (Endogen), PEconjugated mouse anti-human Vg 9 mAb clone B3·1 (BD Biosciences Pharmingen, Cowley, UK), FITC-conjugated mouse anti-human pan-gd mAb clone 5A6.E9 (Endogen), PerCPconjugated mouse anti-human CD3 mAb clone SK7 (BD Biosciences), FITC-conjugated mouse anti-human CD69 mAb clone L78 (BD Biosciences), allophycocyanin (APC)-conjugated mouse anti-human IL2 clone MQ1-17H12 (Caltag-Medsystems Ltd., Siverstone, UK), APC-conjugated mouse anti-human TNFa clone Mab11 (BD Biosciences Pharmingen, Cowley, UK) and APC-conjugated mouse anti-human IFNg clone B27 (BD Biosciences Pharmingen, Cowley, UK).
gd T cell antigens Alkylamines (Sigma) were diluted to a 1 M stock in RPMI media and brought to pH 7·0 with concentrated HCl. Alkylamine stocks were maintained in small aliquots at -80∞C. 1 mM isopentenyl pyrophosphate (Sigma), 1 mM pamidronate (Calbiochem) and 100 mM risedronate (Procter & Gamble) stocks in RPMI were stored in the same way. Tuberculin purified protein derivative (PPD) was purchased from the Statens Seruminstitut IFNg ELISpot gd T cells were washed in RPMI and incubated overnight in R10 at 37∞C. 96-well nitrocellulose plates (Millipore (UK) Ltd., Watford, UK) were incubated overnight at 4∞C with 15 mg/ml anti-human-IFNg primary antibody (clone 1-D1K; Mabtech, AB, Nacka Strand, Sweden). The plates were then washed twice with RPMI and blocked with R10 for 3 h at 37∞C. R10 was decanted by inversion and assays applied to each well before incubation at 37∞C as detailed below. Assays were terminated by washing once in water, followed by 5 washes in PBS. Secondary antibody (anti-human-IFNg-Biotin antibody clone 7-B6-1; Mabtech) was applied at 1 mg/ml and the plate incubated for 100 min at room temperature (RT). The plate was washed 6 times with PBS before application of streptavidin-ALP (1 : 1000 in PBS; Mabtech) for 40 min at RT. After 5 further washes in PBS, spots were revealed by incubation for 15 min at RT with developing buffer (Bio-Rad AP conjugate substrate kit) and counted mechanically using an ELISpot Reader System ELR02 (Autoimmun Diagnostika; Strassberg) after drying. The data displayed has not undergone any manual manipulation. Ltd., Abingdon, UK) as previously described [37] .
gd T cell depletion of PBMC 10 8 human PBMC were incubated with 10 mg/ml anti-human pangd antibody for 30 min on ice. Cells were washed once in 20X labelling volume with PBS/0·1%BSA and resuspended at 4 ¥ 10 7 cells/ml in PBS/0·1%BSA. 2 ¥ 10 7 anti-mouse IgG1 Dynabeads (Dynal Biotech Ltd., Bromborough, UK) washed in PBS/ 0·1%BSA were added and the cells incubated for 1 h at 4∞C with gentle rotation. The tube was then placed in the magnetic particle concentrator (Dynal) and left to separate for 30 min. The supernatant was transferred to a fresh tube. The success of depletion was determined by FACS analysis with the anti-CD3 and pan-gd antibodies detailed above.
Stimulation of gd T lymphocytes for subsequent immunoblotting
Cells were washed twice in RPMI and incubated overnight in R10. The following day, FCS was washed off with two changes of RPMI and 10 6 gd T cells were resuspended in 10 ml of RPMI. After 10 min at 37∞C in 5% CO 2 , T cells were stimulated by incubation with 10 mg/ml anti-CD3 antibody (clone UCHT-1; Amersham) for 3 min. The reaction was stopped by washing once with 1 ml icecold PBS, and resuspending the pellet in cold lysis buffer (140 mM NaCl, 20 mM Tris pH 8·0, 10 mM NaF, 2 mM EDTA, 20% glycerol, 1% IGEPAL, 1 mM Na 3 VO 4 , 10 mg/ml aprotonin, 10 mg/ml leupeptin) at 5 ¥ 10 7 cells/ml. Blots were performed as described previously [38] .
RESULTS

Activation of human peripheral blood gd T cells directly ex vivo
Recent studies have described low molecular weight, nonpeptidic compounds that appear to be able to activate the Vg 9Vd 2 dominant subset of gd T cells in human peripheral blood. These compounds include alkylphosphates [31, 39] , alkylamines [32] and nBPs [33] . We examined IFNg production in response to activating alkylphosphate and alkylamine ligands and compared this to PPD by ELISpot (Fig. 1 ). Significant spot formation was observed with the previously reported [32] gd antigens secbutylamine and isobutylamine. Between 15 and 220 spots were observed per 5 ¥ 10 4 peripheral blood mononuclear cells (PBMC) from nine separate healthy donors (Fig. 2a) . Curiously, ethylamine, isopropylamine, ethanolamine, and isoamylamine did not appear to activate (Fig. 2b ) despite having been previously described as antigenic at the concentration used [32] . However, alkylamines only activate gd T cells at concentrations close to those that are cytotoxic [32] . It is possible that the assays or cells we used were less sensitive than in previous studies so that cells died at alkylamine concentrations below the activation threshold. Magnetic depletion of gd T cells from PBMC (judged to be >90% successful by FACS analysis) removed the vast majority of alkylamineinduced spots (Fig. 1a,b) . Magnetic depletion similarly removed the majority of spots induced by the phosphate antigen isopentenyl pyrophosphate (IPP) (Fig. 1a,b) . Titration showed that IPP was a significantly more potent antigen than the alkylamines (Fig. 2b) . High concentrations of isobutylamine were toxic [32] (Figs 1a and 2b) and also prevented peptide-induced spot formation by ab TCR-expressing cytotoxic T lymphocytes (data not shown). Magnetic-depletion of gd T cells was observed to remove approximately a third of IFNg spot forming cells in response to PPD during overnight ELISpot assay (Fig. 1) . Similar results were obtained using PBMC from two other individuals (data not shown). Vg 9 T cells were shown to respond to IPP, risedronate and PPD in direct ex vivo intracellular cytokine staining (ICS) assays (Fig. 2c) . Examination of T cell activation by CD69 upregulation (Fig. 2d) confirmed the presence of PPD-reactive gd T cells in the PBMC of more than half of the individuals studied. The responses measured by 6 h ICS were significantly lower than those measured by overnight ELISpot or CD69 up-regulation. Far fewer peripheral blood gd T cells up-regulated surface expression of CD69 (<5%) after only 6 h incubation with PPD (data not shown); thus, the difference between ICS and other assays likely reflects the duration of antigen exposure. Overnight ICS assay was toxic to cells.
Characterization of gd T cell clones
In order to characterize peripheral blood gd T cells further, we grew gd T cell clones from human PBMC and screened for those bearing the dominant Vg 9 receptor by flow cytometry with monoclonal antibody clone 7A5 (Endogen). Curiously, 1/60 of the clones that grew expressed a Vg 9 receptor paired with a Vd 1 chain. Two robust Vg 9Vd 2-expressing and the Vg 9Vd 1-expressing clone were taken forward for further analysis. The TCR sequences of these clones (Fig. 3) confirmed these designations but showed that both Vg 9Vd 2-expressing cells expressed an identical TCR. The CDR3 regions of the Vg 9 chain differed in the Vd 1 and Vd 2 clone (Fig. 3) . Both Vg 9 chains used a joining segment encoded by the TCRGJP (Jg P) gene (IMGT nomeclature [36] ). The Vg 9Vd 1 and Vg 9Vd 2 clones expressed high levels of cell surface TCR (Fig. 4a) and could be activated through this TCR by CD3-crosslinking (Fig. 4b) f2  f3  f4  f7  f8  f9  f10  f11  f12   5  9  1 1  14  5  6  10  6  78  81  g1  g2  g3  g4  g7  g8  g9  g10  g11  g12   4  5  3 7  42  44  32  10  10  103  81  h1  h2  h3  h4  h7  h8  h9  h10  h11  h12   4  8  3 0  44  9  6  23  27  96  69 pan gd amounts of MIP1b in response to anti-CD3 cross-linking, IPP, secbutylamine and risedronate (Fig. 4c) . In contrast, the Vg 9Vd 1 clone only responded to anti-CD3 cross-linking and was unable to recognize alkylphosphate, alkylamine or nBP antigens (Fig. 4c) . IFNg ELISpot analysis confirmed that the Vg 9Vd 2 clone activated in response to IPP, secbutylamine and isobutylamine (Fig. 4d) . Activation of the Vg 9Vd 2 clone by low molecular weight nonpeptidic compounds required the presence of both antigen-presenting cells and antigen (data not shown). Curiously, PPD was unable to activate the Vg 9Vd 2 T cell clone. This result contrasts with those of another study which indicated that all Vg 9Vd 2 T cells respond to M. tuberculosis extract including those that are CD4-CD8-, CD8+ or CD4+ [40] . However, these differences might be due to the fact that M. tuberculosis extracts are known to contain pyrophosphate antigens that are lost in the production of PPD. Neither alkylphosphate or alkylamine antigens were able to activate the Vg 9Vd 1-expressing clone in IFNg ELISpot assay (data not shown). 
Vg9Vd2 T cells respond to alkylphosphate/alkylamine antigens and nBP antigens with different kinetics
Recent studies have shown that nBP antigens can be pulsed onto tumour cells [41, 42] . We used IFNg ELISpot to examine whether alkylphosphate, alkylamine and aminobisphosphonate antigens could be pulsed onto antigen presenting cells (Fig. 5) . Alkylphosphate and alkylamine antigens were unable to induce lasting changes to antigen presenting cells and activation was only observed when these antigens were present throughout the assay. In contrast, the nBP antigen, pamidronate, was able to effect changes in antigen presenting cells so that they remained antigenic even after washing (Fig. 5 ).
gd T cell activation by phosphate and alkylamine antigens requires contact with cells of human origin
Analysis of T cell activation by IFNg ELISpot has the benefit of utilizing very few cells. Such a low number of cells spread out in a 96-well flat bottomed plate are unlikely to contact each other. Indeed no spots were seen if antigen was added in the absence of presenting cells (Fig. 6) . Antigen recognition could be restored by the addition of cell lines of human origin. The appearance of spots when Vg 9Vd 2 cells were plated at a higher density indicated that gd T cells were able to present antigen to themselves. The mouse myeloma P3/NS1/1-Ag4-1 (ECACC 85011427) and the rat myeloma Y3.AG.1.2.3 (ECACC 85110502) cell lines were unable to 'present' phosphate or alkylamine antigens to Vg 9Vd 2 T cells. We tested nine different human cell lines, including those deficient in b2-micoglobulin and MHC class I, and were unable to find a nucleated human cell line that did not present these antigens, or nBP antigens, to Vg 9Vd 2 T cells (data not shown). Activation always required both antigen presenting cells (APC) and antigen. Human erythrocytes were unable to function as APC in our assays (data not shown).
DISCUSSION
Recent studies have documented that T cells expressing a Vg 9Vd 2 TCR, usually the dominant subset of gd T cells in human peripheral blood, can activate in response to alkylphosphate, alkylamine or nBP antigens [31] [32] [33] 39] . We have extended these observations [36] is used throughout this work). The g and d chain sequences for the Vg 9Vd1 clone have the accession numbers AJ583014 and AJ583015, respectively, at the EMBL Nucleotide Sequence Database. The accession numbers AJ583012 and AJ583013 have been assigned to the g and d chains for the Vg 9Vd2 clone. The CDR1, 2 and 3 sequences are indicated by shaded boxes. The differences in the Vg 9 CDR3 region between the Vd1 and Vd2 clones are underlined. Both Vg 9 chains use the Jg P joining region which contains two germline encoded lysine residues (shown in bold text within the CDR3 region) that have been shown to be essential for recognition of alkylphosphate and alkylamine ligands [46] . clones were shown to express high levels of TCR by FACS. Clones were stained with PE-conjugated anti-human Vg 9 mAb clone B3·1 (all panels), FITC-conjugated anti-human Vd1 mAb clone TS8·2 (left panels) and FITC-conjugated anti-human Vd2 mAb clone B6·1 (right panels). (b) Both clones can be activated through their TCR by anti-CD3 antibody. Clones were stimulated with anti-CD3 antibody (10 mg/ ml) for 3 min, washed once with PBS, and lysed, before separation by SDS-PAGE alongside unstimulated controls. Proteins bearing phosphorylated tyrosine residues were revealed by immunoblotting with anti-phosphotyrosine antibody clone 4G10 as described [38] . by showing that all of these antigens can stimulate a population of gd T cells in direct ex vivo IFNg ELISpot assay. The numbers of Vg 9Vd 2 T cells measured by FACS analysis of PBMC indicate that only approximately 10% of these cells respond to alkylphosphate, alkylamine and nBP antigens. This may reflect the proportion of cells that recognize these antigens or the proportion that make IFNg when they respond. However, only approximately 30% of a clonal Vg 9Vd 2 T cell population were able to produce spots in IFNg ELISpot assay (Fig. 4d) . This percentage is roughly the same as that observed for more than 20 different ab TCRexpressing cytotoxic T lymphocyte (CTL) clones in response to cells presenting their cognate peptide-MHC antigen (unpublished data). We also show that the number of cells that activate in IFNg ELISpot is dependent on the antigen-presenting cell (Fig. 6) . Variation in the ability of different cells to act as presenting cells may reflect differences in the surface expression of ICAM-1 [42] or differences in the surface expression a true gd T cell ligand presentation molecule. A recent study defined four subsets of human Vd2 T cells in peripheral blood based on the expression of CD45RA and CD27 [43] . Only the CD45RA -CD27 -population of Vd 2-expressing cells were able to make large amounts of IFNg in response to IPP [43] . CD45RA -CD27 -were found to make up 26·5 ± 15·3% of Vd2 T cells in the peripheral blood of 15 healthy adults [43] . It is possible that we are only able to detect this population of Vd2 cells in our IFNg ELISpots. We also find that in more than half the individuals we examined, 25-35% of the cells that produce IFNg in response to PPD express a gd TCR (Fig. 1) . PPD-induced activation of gd T cells was confirmed by FACS analysis (Fig. 2c) . These data are in accordance with early studies that show an expansion of gd T cells in the lungs of mice exposed to aerosolized PPD [44] as well as those showing expansion of the human Vg9Vd2 T cell population in vivo in M. tuberculosis infection [4] and after BCG vaccination [29] . We have not determined the exact nature of the gd T cell ligands in PPD and it is possible that the PPD-induced activation of gd T cells could have been due to low-level contamination of this preparation with mycobacterial alkylphosphate antigens or to the presence of Toll-like receptor ligands.
To examine their activation requirements further, we cloned Vg 9-expressing T cells from peripheral blood. We found that Vg 9Vd 1 T cells are unable to recognize the plethora of nonpeptide antigens recognized by cells expressing Vg 9 in its more common pairing with a Vd 2 chain (Fig. 4c) . This result is in agreement with those of a previous study that showed Vg 9Vd1 T cell clones failed to respond to monoethyl phosphate [31] . A previous study demonstrated that transfection of TCR-negative Jurkat T cells with a Vg 9Vd 2 TCR, but not a Vd1 TCR (not paired with Vg 9), enabled recognition of alkylphosphate antigen [45] . These elegant experiments further highlight that T cell recognition of such antigens requires the expression of a specific gd TCR. Minato and colleagues have recently extended these observations by showing that recognition of alkylphosphate, alkylamines and nBP antigens by Vg 9Vd 2 T cells requires that the Vg 9 segment be joined to a Jg P joining region [46] . Previous experiments have shown that the proportion of V9JPC1 g chains is significantly higher in the peripheral blood than in thymocytes [47] . The peripheral expansion of Vg 9 cells using Jg P appears to be antigen-driven [48] . The gd T cells in cord blood mononuclear cells (CBMC) express a diverse repertoire of gd TCRs [48] . Stimulation of CBMC with alkylphosphate antigen, but not with PHA, induces the preferential expansion of T cells bearing Vg 9Vd 2 TCRs [48] . 70% of TCRs expanded with alkylphosphate antigen use a Jg P joining region compared to just 20% of those cells expanded with PHA [48] . The Jg P joining region differs from other possible joining regions in that it contains two germline encoded lysine residues (K 1 & K 2 ) in addition to a third lysine (K 3 ) that is conserved in all Jg [36, 46] . Mutation of these lysine residues completely abrogated the ability of these TCRs to respond to nonpeptide antigens [46] . Both the Vg 9Vd1 and Vg 9Vd 2 clones tested here bear Vg 9JP chains (Fig. 3) . As only the Vd 2 clone is able to respond to alkylphosphate, alkylamine and nBP antigens (Fig. 4c) it would appear that the Vd 2 chain may also make an essential contribution to the recognition of these ligands. Recent results appear to confirm that specific features of the Vd 2 chain are required for recognition of nonpeptide antigens by Vg 9Vd 2 T cells [48] . It is further noteworthy that the amount of MIP1b manufactured by Vg 9Vd 2 T cells (Fig. 4c ) is comparable to that we have measured after antigen-induced activation of CTL [37] . The release of b-chemokines by gd T cells may act to recruit immune cells to sites of infection [49] . We show that a clonal population of Vg 9Vd 2 T cells can recognize alkylphosphate, alkylamine and nBP ligands (Figs 4 and  5) . Bukowski et al. [32] also demonstrated that a single T cell clone could recognize two types of ligand; alkylamines and IPP. The authors suggest that, given the small sizes of these antigens, a single gd TCR might either possess two different binding sites or a single binding site that can accommodate both types of ligand. Our finding that the recognition of both these antigens and nBP antigens requires cell surface presentation makes it highly unlikely that there are separate binding sites for these classes of ligand. Indeed, it is very difficult to envisage just how single Vg 9Vd 2 TCRs are able to respond to such different chemical species and yet still exhibit tight structural constraints within each class of ligand. The most obvious similarity between the recognized ligands is their alkyl chains. While it is known that phosphate antigens require their phosphate and nBPs and alkylamines require their amino groups for their antigenicity [32, 33, 39] it is possible that this is necessary for anchoring them to a presenting molecule rather than forming a component of the TCR-docking structure. Indeed, the finding that both antigenic alkylphosphate and alkylamine ligands require similar alkyl chains for recognition lends some credence to such a hypothesis and has lead to attempts at molecular prediction [50] . However, it is noticeable that the most potent nBP antigen to date, risedronate, which can stimulate gd T cell expansion from human PBMC at concentrations as low as 10 nM [35] was not included in this predictive exercise [50] . We have also shown that risedronate can activate Vg 9Vd 2 T cells in IFNg ELISpot assay at concentrations of <1 mM (Fig. 4c and data not shown) . Risedronate has an aromatic ring and does not fit with the pattern recognition hypothesis championed by Gossman and Oldfield [50] .
It is noteworthy that antigenic nBPs, and not their corresponding nonantigenic nonaminobisphosphonates (BPs), are potent inhibitors of the mevalonate pathway (reviewed in [51] ). It must be no coincidence that IPP, a potent activator of Vg 9Vd 2 T cells, is part of this metabolic pathway. Indeed, treatment of cells with the nBPs zoledronate and pamidronate has recently been shown to lead to an accumulation of IPP [52] . It thus seems likely that antigenic nBPs exert their effects via IPP and not directly as previously assumed [41, 42, 50] . The results of De Libero and colleagues [52] elegantly demonstrate this mode of action for nBPs by two different means. First, they show that nBPs, unlike IPP, require internalization in order to exert their effects [52] . Second, they show that blocking the production of IPP inhibits the ability of nBPs to activate gd T cells [52] . A model in which nBPs function via metabolites in the mevanolate pathway conveniently explains some current anomalies in the activation of gd T cells by these compounds. Firstly, it indicates how the nBPs risedronate (Fig. 5 ) and zoledronate [52] , the aromatic ring structures of which do not fit with the established pattern recognition motif for gd antigens [50] , might lead to activation. Secondly, it explains why BPs that do not inhibit the mevalonate pathway [51] fail to act as antigens ( [52] and our unpublished data). This mechanism of action also explains why the nBP pamidronate has been described as being 'rather unique' amongst non peptide antigens in that it could be pulsed onto antigen presenting cells and retain its antigenicity after these cells had subsequently been washed ( [41, 42] and Fig. 5 ). However, although unlikely, it still remains possible that nBPs activate Vg 9Vd 2 Tcells directly. Some of the findings of Gober et al. [52] could potentially be due to the toxic effects of statins. Statins and bisphosphonates have inhibitory effects on almost all cells as blocking the mevanolate pathway leads to the loss of Ras and other receptor signals due to the blockade of protein prenylation [53] . nBPs block farnesyl synthase and may act synergistically with inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase to kill cells. These effects may be overcome by further addition of intermediates in the mevalonate pathway. The significance of these issues is apparent in the clinical setting. nBPs have become well established as clinically successful antiresorptive agents for the treatment of osteoporosis (reviewed in [51] ) and, more recently, multiple myeloma [54, 55] . These drugs can induce a transient fever and biological changes, including specific cytokine production, that are suggestive of an acute phase response (e.g. [56] [57] [58] ). It is possible that the build up of IPP and other metabolites resulting from the actions of these drugs on the mevalonate pathway and the ensuing activation of gd T cells in vivo might contribute to these side-effects. Further work aimed at testing this hypothesis is required.
Any attempt to understand the recognition requirements of gd T cells should also take the absolute requirement for speciesspecific cell-cell contact into account. The use of IFNg ELISpot has allowed us to conclusively prove the need for cell-cell contact with a cell of human origin. The results of Morita et al. [40] showing that monoethyl phosphate-induced calcium flux in Vg 9Vd 2 T cells required that the cells be centrifuged and resuspended, and those of Lang et al. [59] showing that Vg 9Vd 2 T cells responded to mycobacterial phosphoantigens poorly when kept in suspension first hinted that cell-cell contact might be important for activation. During the preparation of this manuscript another group have shown that recognition of the nBP pamidronate also requires species-specific cell-cell contact [42] . This study showed that 33 tumour cell lines from 12 different species, including other primates, failed to mediate Vg 9Vd 2 T cell activation in response to pamidronate [42] . Curiously, pamidronate did not activate gd T cells when 'presented' by 5 human tumour cell lines [42] . Recognition of some, but not all, of these cell lines could be restored by transfection with ICAM-1 [42] . However, pamidronate likely functions indirectly via its actions on IPP synthesis rather than as a direct 'ligand' as this study assumed and it remains possible that these cell lines have an abnormal mevalonate pathway. It is important that these experiments be repeated with IPP itself. Human cell lines that fail to present Vg 9Vd 2 T cell antigens are likely to be very useful tools in the elucidation of the antigenpresentation mechanism.
That gd T cell activation requires cell-cell contact with a cell of human origin (Fig. 6 ) opens up a number of possibilities. First, it could be indicative of a human-specific gd T cell ligandpresentation molecule. The ability of multiple cell lines from different tissues and individuals to act as antigen-presenting cells argues against any kind of large variability in this molecule as seen for the MHC genes. Alkylphosphate and alkylamine antigens are unable to effect stable changes in the antigen presenting cells as their effects are readily removed by dilution and washing [40] (Fig. 5, and our unpublished observation) . This argues against major changes in the surface of the presenting cell such as upregulation of a gd TCR ligand or heat shock proteins such as MIC-A and MIC-B [60] [61] [62] . Second, the requirement for presentation by a human cell may be indicative of a human specific coreceptor element or the requirement for additional costimulatory signals. Distinguishing between these various models awaits the characterization of the true ligand for peripheral blood Vg 9Vd 2 T cells. The recent production of a high purity, soluble Vg 9Vd 2 TCR [63] should aid in this process. Only when we understand exactly what the gd TCR recognizes will we be able to unlock the forgotten third arm of adaptive immunity that gd T cells control.
